Works by Nakamura, Keiichi

Results: 14
    1
    2
    3
    4

    Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001.

    Published in:
    Japanese Journal of Clinical Oncology, 2025, v. 55, n. 3, p. 253, doi. 10.1093/jjco/hyae168
    By:
    • Tateishi, Kazunari;
    • Mizugaki, Hidenori;
    • Ikezawa, Yasuyuki;
    • Morita, Ryo;
    • Yokoo, Keiki;
    • Sumi, Toshiyuki;
    • Aso, Mari;
    • Kikuchi, Hajime;
    • Nakamura, Atsushi;
    • Sekikawa, Motoki;
    • Yoshiike, Fumiaki;
    • Kitamura, Yasuo;
    • Kimura, Nozomu;
    • Hachiya, Tsutomu;
    • Tsurumi, Kyoji;
    • Agatsuma, Toshihiko;
    • Megumi, Furuta;
    • Nakamura, Keiichi;
    • Jingu, Daisuke;
    • Yamamoto, Hiroshi
    Publication type:
    Article
    5
    6

    Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status.

    Published in:
    BMC Pulmonary Medicine, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12890-024-03212-5
    By:
    • Taniguchi, Yoshihiko;
    • Tamiya, Akihiro;
    • Osuga, Mitsuo;
    • Harada, Daijiro;
    • Isa, Shun-ichi;
    • Nakamura, Keiichi;
    • Mizumori, Yasuyuki;
    • Shinohara, Tsutomu;
    • Yanai, Hidetoshi;
    • Nakatomi, Katsumi;
    • Oki, Masahide;
    • Mori, Masahide;
    • Kuwako, Tomohito;
    • Yamazaki, Koji;
    • Tamura, Atsuhisa;
    • Ando, Masahiko;
    • Koh, Yasuhiro
    Publication type:
    Article
    7

    Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study (HOT2101).

    Published in:
    Cancer Science, 2024, v. 115, n. 4, p. 1273, doi. 10.1111/cas.16094
    By:
    • Tsuji, Kosuke;
    • Mizugaki, Hidenori;
    • Yokoo, Keiki;
    • Kobayashi, Maki;
    • Kawashima, Yosuke;
    • Kimura, Nozomu;
    • Yokouchi, Hiroshi;
    • Kikuchi, Hajime;
    • Sumi, Toshiyuki;
    • Kawai, Yasutaka;
    • Kobashi, Kenta;
    • Morita, Ryo;
    • Ito, Kenichiro;
    • Kitamura, Yasuo;
    • Minemura, Hiroyuki;
    • Nakamura, Keiichi;
    • Aso, Mari;
    • Honjo, Osamu;
    • Tanaka, Hisashi;
    • Takashina, Taichi
    Publication type:
    Article
    8

    Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expression.

    Published in:
    Cancer Science, 2022, v. 113, n. 6, p. 2109, doi. 10.1111/cas.15361
    By:
    • Ikezawa, Yasuyuki;
    • Mizugaki, Hidenori;
    • Morita, Ryo;
    • Tateishi, Kazunari;
    • Yokoo, Keiki;
    • Sumi, Toshiyuki;
    • Kikuchi, Hajime;
    • Kitamura, Yasuo;
    • Nakamura, Atsushi;
    • Kobayashi, Maki;
    • Aso, Mari;
    • Kimura, Nozomu;
    • Yoshiike, Fumiaki;
    • Furuta, Megumi;
    • Tanaka, Hisashi;
    • Sekikawa, Motoki;
    • Hachiya, Tsutomu;
    • Nakamura, Keiichi;
    • Shimokawa, Mototsugu;
    • Oizumi, Satoshi
    Publication type:
    Article
    9

    Circulating Tumour DNA in Patients With EGFR‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study.

    Published in:
    Cancer Medicine, 2025, v. 14, n. 7, p. 1, doi. 10.1002/cam4.70861
    By:
    • Tamiya, Akihiro;
    • Mizumori, Yasuyuki;
    • Osuga, Mitsuo;
    • Isa, Shun‐ichi;
    • Taniguchi, Yoshihiko;
    • Nakamura, Keiichi;
    • Harada, Daijiro;
    • Shinohara, Tsutomu;
    • Yanai, Hidetoshi;
    • Nakatomi, Katsumi;
    • Oki, Masahide;
    • Mori, Masahide;
    • Kuwako, Tomohito;
    • Yamazaki, Koji;
    • Tamura, Atsuhisa;
    • Ando, Masahiko;
    • Koh, Yasuhiro
    Publication type:
    Article
    10

    Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis.

    Published in:
    Cancer Medicine, 2024, v. 13, n. 14, p. 1, doi. 10.1002/cam4.70036
    By:
    • Ikezawa, Yasuyuki;
    • Morita, Ryo;
    • Mizugaki, Hidenori;
    • Tateishi, Kazunari;
    • Yokoo, Keiki;
    • Sumi, Toshiyuki;
    • Kikuchi, Hajime;
    • Kitamura, Yasuo;
    • Nakamura, Atsushi;
    • Kobayashi, Maki;
    • Aso, Mari;
    • Kimura, Nozomu;
    • Yoshiike, Fumiaki;
    • Megumi, Furuta;
    • Tanaka, Hisashi;
    • Sekikawa, Motoki;
    • Hachiya, Tsutomu;
    • Nakamura, Keiichi;
    • Hommura, Fumihiro;
    • Sukoh, Noriaki
    Publication type:
    Article
    11

    Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 10, p. 11525, doi. 10.1002/cam4.5889
    By:
    • Daisuke Morinaga;
    • Hajime Asahina;
    • Shotaro Ito;
    • Osamu Honjo;
    • Hisashi Tanaka;
    • Ryoichi Honda;
    • Hiroshi Yokouchi;
    • Keiichi Nakamura;
    • Kei Takamura;
    • Fumihiro Hommura;
    • Yasutaka Kawai;
    • Kenichiro Ito;
    • Noriaki Sukoh;
    • Keiki Yokoo;
    • Ryo Morita;
    • Toshiyuki Harada;
    • Taichi Takashina;
    • Tomohiro Goda;
    • Hirotoshi Dosaka-Akita;
    • Hiroshi Isobe
    Publication type:
    Article
    12
    13

    Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA.

    Published in:
    Investigational New Drugs, 2025, v. 43, n. 1, p. 101, doi. 10.1007/s10637-024-01500-9
    By:
    • Taniguchi, Yoshihiko;
    • Tamiya, Akihiro;
    • Osuga, Mitsuo;
    • Isa, Shun-ichi;
    • Nakamura, Keiichi;
    • Mizumori, Yasuyuki;
    • Shinohara, Tsutomu;
    • Yanai, Hidetoshi;
    • Nakatomi, Katsumi;
    • Oki, Masahide;
    • Mori, Masahide;
    • Kuwako, Tomohito;
    • Yamazaki, Koji;
    • Shimada, Masahiro;
    • Ando, Masahiko;
    • Koh, Yasuhiro
    Publication type:
    Article
    14